Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Best Response to HD IL-2

From: Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Type Best Response mM
(N = 40)
mRCC
(N = 17)
Initial Response Complete Response 0 (0) 1 (6)
Partial Response 3 (8) 1 (6)
Stable Disease 20 (50) 9 (53)
Progressive Disease 17 (42) 6 (35)
Best Overall Response Complete Response 4 (10) 2 (12)
Partial Response 5 (13) 2 (12)
Stable Disease 15 (37) 8 (47)
Progressive Disease 16 (40) 5 (29)